DXCM Earnings

DXCM reported its earnings on 2026-04-30, showcasing a revenue of 1.19B against an estimate of 1.18B, resulting in a 1.01% surprise. The EPS was 0.56, surpassing the expected 0.47 by 19.15%. The stock experienced a 3.02% price change on the earnings day and a 1.36% change over the next five days, reflecting market reactions to the results.

Following DXCM's earnings announcement on 2026-04-30, the stock price moved by 3.02% on the day of the release. Over the subsequent five days, it saw a 1.36% change. Historically, DXCM's stock price tends to shift by an average of 0.84% in the 10 days leading up to earnings and -3.83% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate DXCM's annual revenue to reach 1.29B, while the EPS is projected at 0.60. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between DXCM's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, DXCM's stock price typically moves by 0.84% in the 10 days before its earnings and -3.83% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.60 and revenue of 1.29B.

The earnings call summary and Q&A session reveal positive sentiment. DexCom shows strong financial performance and optimistic guidance with revenue growth projected at 11%-13%. There are promising developments in product launches and expansion of Medicare coverage, particularly for the type 2 non-insulin population. Record new patient starts and international growth further support positive outlook. Although there is some uncertainty about the exact timing of CMS coverage, the overall tone is optimistic. The strategic focus on capital allocation and potential share buybacks also contributes positively to the sentiment.